122 related articles for article (PubMed ID: 37751589)
1. Translocation Processes of Pt(II)-Based Drugs through Human Breast Cancer Cell Membrane:
Almeida ER; Goliatt PVZC; Dos Santos HF; Picaud F
J Chem Inf Model; 2023 Oct; 63(19):6141-6155. PubMed ID: 37751589
[TBL] [Abstract][Full Text] [Related]
2. Unveiling the Releasing Processes of Pt(II)-Based Anticancer Drugs from Oxidized Carbon Nanohorn: An In Silico Study.
Almeida ER; Capriles PVSZ; Dos Santos HF
J Phys Chem B; 2022 Jun; ():. PubMed ID: 35670834
[TBL] [Abstract][Full Text] [Related]
3. Carbon nanohorns as nanocontainers for cisplatin: insight into their interaction with the plasma membranes of normal and breast cancer cells.
Almeida ER; Dos Santos HF; Capriles PVSZ
Phys Chem Chem Phys; 2021 Aug; 23(30):16376-16389. PubMed ID: 34318822
[TBL] [Abstract][Full Text] [Related]
4. Modeling the Cellular Uptake of Functionalized Carbon Nanohorns Loaded with Cisplatin through a Breast Cancer Cell Membrane.
Almeida ER; Goliatt PVZC; Dos Santos HF; Picaud F
Mol Pharm; 2024 Jan; 21(1):38-52. PubMed ID: 37646561
[TBL] [Abstract][Full Text] [Related]
5. Molecular Dynamics Simulations Based on Polarizable Models Show that Ion Permeation Interconverts between Different Mechanisms as a Function of Membrane Thickness.
Chen P; Vorobyov I; Roux B; Allen TW
J Phys Chem B; 2021 Feb; 125(4):1020-1035. PubMed ID: 33493394
[TBL] [Abstract][Full Text] [Related]
6. Novel 4-Amino-Quinazoline moieties ligated Platinum(IV) prodrugs overcome cisplatin resistance in EGFR
Li R; Zhao W; Jin C; Xiong H
Bioorg Chem; 2023 Jun; 135():106499. PubMed ID: 37058978
[TBL] [Abstract][Full Text] [Related]
7. Evaluation for Synergistic Effects by Combinations of Photodynamic Therapy (PDT) with Temoporfin (mTHPC) and Pt(II) Complexes Carboplatin, Cisplatin or Oxaliplatin in a Set of Five Human Cancer Cell Lines.
Lange C; Bednarski PJ
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30332729
[TBL] [Abstract][Full Text] [Related]
8. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds.
Meijer C; Mulder NH; Timmer-Bosscha H; Sluiter WJ; Meersma GJ; de Vries EG
Cancer Res; 1992 Dec; 52(24):6885-9. PubMed ID: 1458477
[TBL] [Abstract][Full Text] [Related]
9. Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status.
Martelli L; Di Mario F; Botti P; Ragazzi E; Martelli M; Kelland L
Biochem Pharmacol; 2007 Jun; 74(1):20-7. PubMed ID: 17466278
[TBL] [Abstract][Full Text] [Related]
10. Comparable effectiveness and immunomodulatory actions of oxaliplatin and cisplatin in electrochemotherapy of murine melanoma.
Ursic K; Kos S; Kamensek U; Cemazar M; Scancar J; Bucek S; Kranjc S; Staresinic B; Sersa G
Bioelectrochemistry; 2018 Feb; 119():161-171. PubMed ID: 29024870
[TBL] [Abstract][Full Text] [Related]
11. Platinum(II) complexes of imidazophenanthroline-based polypyridine ligands as potential anticancer agents: synthesis, characterization, in vitro cytotoxicity studies and a comparative ab initio, and DFT studies with cisplatin, carboplatin, and oxaliplatin.
Alexander C; Nithyakumar A; Paul MWB; Arockia Samy N
J Biol Inorg Chem; 2018 Jul; 23(5):833-848. PubMed ID: 29934700
[TBL] [Abstract][Full Text] [Related]
12. Novel Pt(IV) prodrug self-assembled nanoparticles with enhanced blood circulation stability and improved antitumor capacity of oxaliplatin for cancer therapy.
Fu Y; Kong Y; Li X; Cheng D; Hou Y; Li Y; Li T; Xiao Y; Zhang Q; Rong R
Drug Deliv; 2023 Dec; 30(1):2171158. PubMed ID: 36744299
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells.
Samimi G; Safaei R; Katano K; Holzer AK; Rochdi M; Tomioka M; Goodman M; Howell SB
Clin Cancer Res; 2004 Jul; 10(14):4661-9. PubMed ID: 15269138
[TBL] [Abstract][Full Text] [Related]
14. Effect of tumor presence on cisplatin and carboplatin: disposition in the isolated, perfused tumor and skin flap.
Vaden SL; Williams PL; Page RL; Riviere JE
Cancer Chemother Pharmacol; 1993; 32(1):31-8. PubMed ID: 8462121
[TBL] [Abstract][Full Text] [Related]
15. Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporter.
Helleman J; Burger H; Hamelers IH; Boersma AW; de Kroon AI; Stoter G; Nooter K
Cancer Biol Ther; 2006 Aug; 5(8):943-9. PubMed ID: 16775422
[TBL] [Abstract][Full Text] [Related]
16. A recombinant platform to characterize the role of transmembrane protein hTMEM205 in Pt(II)-drug resistance and extrusion.
Gallenito MJ; Qasim TS; Tutol JN; Prakash V; Dodani SC; Meloni G
Metallomics; 2020 Oct; 12(10):1542-1554. PubMed ID: 32789331
[TBL] [Abstract][Full Text] [Related]
17. Unassisted N-acetyl-phenylalanine-amide transport across membrane with varying lipid size and composition: kinetic measurements and atomistic molecular dynamics simulation.
Lee BL; Kuczera K; Lee KH; Childs EW; Jas GS
J Biomol Struct Dyn; 2022 Mar; 40(4):1445-1460. PubMed ID: 33034537
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin.
Fukuda M; Ohe Y; Kanzawa F; Oka M; Hara K; Saijo N
Anticancer Res; 1995; 15(2):393-8. PubMed ID: 7763011
[TBL] [Abstract][Full Text] [Related]
19. [Effects of hyperthermia combined platinum-based drugs on ovarian cancer cell lines SKOV3].
Xie D; Yin RT; Li KM; Xiao P; Tong LX
Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 45(4):606-11. PubMed ID: 25286685
[TBL] [Abstract][Full Text] [Related]
20. The expression of copper transporters associated with the ototoxicity induced by platinum-based chemotherapeutic agents.
Perde-Schrepler M; Fischer-Fodor E; Virag P; Brie I; Cenariu M; Pop C; Valcan A; Gurzau E; Maniu A
Hear Res; 2020 Mar; 388():107893. PubMed ID: 32006874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
